ABSTRACT
Patients with metastatic pancreatic cancer achieved a overall survival of over 12 months using the FOLFIRINOX regimen. However, grade 3-4 hematologic side-effects were up to 49%.
Forty-four patients with metastatic pancreatic cancer were included in the study. 30 patients were male (68.2%) and 14 were female (31.8%). The mean age of the patients was 58.7 (34-73) years. Our median follow-up was 14 months. When the metastatic sites of the patients were examined, 72.7% had liver, 18.2% lung, 18.2% peritoneal, 4.5% lymph nodes and 4.5% bones metastases. There was 40.9% partial response, 13.6% stable disease and 45.4% progression disease in the patients. The median progression- free survival time was 8 months (95% CI 4-12). Median overall survival time was 14 months (95% CI 10.3-17.7), 6 months overall survival was 76.2%, 12 months overall survival was 57.5% and 24 months overall survival was 6%. Grade 3-4 neuropeni was found in 36.4% (grade 3, 27.3%, grade 4 9.1%) and grade 3-4 thrombocytopenia was found in 13.6% of the patients. Grade 3-4 anemia was seen in 14.6% of the patients.Grade 3-4 diarrhea was seen in 4.5% of cases, although grade 1-2 diarrhea was 68% with nonhematologic side effects. Grade 1-2 peripheral sensory neuropathy was observed in 72.7% of the cases, whereas grade 3-4 sensory neuropathy was not detected.
The study was designed as retrospective multicenter. Patients with metastatic pancreatic cancer treated with the first series FOLFIRINOX regimen between the years 2012-2016 were included.
The use of the FOLFIRINOX regimen in the treatment of metastatic pancreatic cancer prolonged both progression-free survival and overall survival. We wanted to retrospectively investigate the efficacy and safety of firstline FOLFIRINOX regimen use in patients with metastatic pancreatic cancer in the Turkish population.